GlassScriptPhysician profile
Michael Jacob Schatz
NPI 1801456181
$1,411.78
in general payments reported to CMS, 2019-2025
16 companies · $602 in 2025
The $602 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $99.99 · 2022: $150 · 2023: $235 · 2024: $325 · 2025: $602.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,162.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,161.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $572.00 | 2022-2025 | Clareon, Clareon Panoptix Pro, Hydrus Microstent |
| Amgen INC. | $125.41 | 2024-2025 | Tepezza |
| Allergan, INC. | $99.99 | 2020 | |
| Lensar, INC. | $95.48 | 2025 | Lensar Laser System |
| Glaukos Corporation | $83.34 | 2024 | Istent Trabecular Micro-Bypass System Model Is3 |
| Tarsus Pharmaceuticals, INC. | $70.35 | 2024-2025 | Xdemvy |
| Johnson & Johnson Surgical Vision, INC. | $56.75 | 2025 | Tecnis Simplicity |
| Dompe US, INC. | $56.49 | 2025 | Oxervate |
| Bausch & Lomb Americas INC. | $53.50 | 2023-2025 | Vyzulta, Envista Mx60 Iol |
| Sight Sciences, INC. | $41.81 | 2024 | Omni Surgical System |
| Mallinckrodt Hospital Products INC. | $35.24 | 2025 | Acthar |
| Harrow Eye, LLC | $31.35 | 2025 | Vevye |
| Ethicon US, LLC | $27.99 | 2023 | Stratafix, Dermabond, Surgicel Nu-Knit |
| Alimera Sciences, INC. | $24.96 | 2024 | Iluvien, Yutiq |
| Rxsight INC | $20.98 | 2025 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $16.14 | 2023 | Tepezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Schatz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.